Clinical Trial Update: A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/Ib-II study to determine the maximum tolerated dose of AUY922 alone and with bortezomib, with or without dexamethasone, in relapsed or refractory mult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• AUY922 (luminespib)
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED